Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7980548 | 0.98 | HSD11B1 (0.41) | HSD11B1 | |
| SCHEMBL1043082 | 0.64 | — | — | |
| SCHEMBL7552932 | 0.63 | — | — | |
| SCHEMBL2807409 | 0.60 | HSD11B1 (0.41) | HSD11B1 | |
| SCHEMBL2805815 | 0.60 | CYP2C19 (0.45) | HSD11B1 | |
| SCHEMBL3243001 | 0.59 | — | — | |
| SCHEMBL13216478 | 0.59 | HSD11B1 (1.00) | HSD11B1 | |
| SCHEMBL3495245 | 0.58 | CYP2C19 (0.48) | HSD11B1 | |
| SCHEMBL840651 | 0.58 | CYP2C19 (0.48) | HSD11B1 | |
| SCHEMBL14084349 | 0.58 | HSD11B1 (0.40) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6538148-B2 | Catalytic hydrogenation | WARNER-LAMBERT COMPANY | 2003-03-25 | — | — | US | claimed |
| US-20020010371-A1 | Process for preparing a cyclic amino acid anticonvulsant compound | DEERING CARL FRANCIS (US) | 2002-01-24 | — | — | US | claimed |
| WO-1999018063-A2 | PROCESS FOR PREPARING A CYCLIC AMINO ACID ANTICONVULSANT COMPOUND | WARNER-LAMBERT COMPANY (US) | 1999-04-15 | — | — | WO | claimed |
| WO-2010023694-A2 | CRYSTALLINE FORMS OF GABAPENTIN AND PROCESS THEREOF | HIKAL LTD (IN) | 2010-03-04 | — | — | WO | disclosed |
| US-7635717-B2 | Process for the preparation of amino methyl cyclo alkane acetic acids | HIKAL LIMITED (IN) | 2009-12-22 | — | — | US | disclosed |
| US-20060149099-A1 | Process for the preparation of amino methyl cyclo alkane acetic acids | HIKAL LIMITED | 2006-07-06 | — | — | US | disclosed |
| US-6538148-B2 | Catalytic hydrogenation | WARNER-LAMBERT COMPANY | 2003-03-25 | — | — | US | disclosed |
| US-20020010371-A1 | Process for preparing a cyclic amino acid anticonvulsant compound | DEERING CARL FRANCIS (US) | 2002-01-24 | — | — | US | disclosed |
| US-6294690-B1 | REACTING BENZONITRILE WITH ALKALI METAL IN AMMONIA OR AMINE IN SOLVENT TO FORM ANIONIC INTERMEDIATE, ALKYLATING WITH HALOACETIC ACID, HYDROGENATING RING, HYDROGENATING NITRILE TO AMINE TO PRODUCE GABAPENTIN | WARNER-LAMBERT COMPANY | 2001-09-25 | — | — | US | disclosed |
| WO-1999018063-A2 | PROCESS FOR PREPARING A CYCLIC AMINO ACID ANTICONVULSANT COMPOUND | WARNER-LAMBERT COMPANY (US) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060149099-A1 | Process for the preparation of amino methyl cyclo alkane acetic acids | GABRA1, GABRA6, ACMSD | HSD11B1 438/4885 |
| US-20020010371-A1 | Process for preparing a cyclic amino acid anticonvulsant compound | BCAT1, BCAT2, GABRA6 | HSD11B1 2137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.